• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A 型链球菌二价疫苗的免疫原性。

Immunogenicity of a divalent group A streptococcal vaccine.

机构信息

Department of Cardiology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 510700, China.

出版信息

Rheumatol Int. 2013 Apr;33(4):1013-20. doi: 10.1007/s00296-012-2455-8. Epub 2012 Aug 8.

DOI:10.1007/s00296-012-2455-8
PMID:22872049
Abstract

We designed and recombined the polypeptide based on the M protein of group A streptococci (GAS)--the causative pathogen of rheumatic fever and rheumatic heart disease, which would be a divalent vaccine to prevent and defend the diseases in relation to the different GAS strains. A divalent vaccine comprising three different peptide epitopes of the antiphagocytic M protein of GAS--an aminoterminal specific sequences, respectively, from the M1 and M12 proteins and J14 peptide (ASREAKKQVEKALE) within the highly conserved C-terminal repeat region of the M1 and M12 proteins--was subcutaneously delivered to mice with the adjuvant. Furthermore, the antisera titers of mice inoculated with the divalent vaccine were assayed by ELISA, and then opsonization and percentage killing against two different GAS serotypes were completed. Our data demonstrated that antisera raised against the divalent vaccine containing amino acids and M-protein-conserved C repeat region are able to kill several GAS strains isolated from the Guangzhou population. Therefore, the divalent vaccine can be used to prevent those diseases caused by GAS in an endemic area. We successfully construct the M-protein-based divalent vaccine that can bring out a high-level antisera titer of mice vaccinated with it. So, the vaccine has the potential to be used to prevent diseases caused by GAS in our country.

摘要

我们设计并重组了基于 A 组链球菌(GAS)的 M 蛋白的多肽,GAS 是风湿热和风湿性心脏病的致病病原体,这将是一种二价疫苗,可以预防和抵御与不同 GAS 菌株相关的疾病。一种二价疫苗包含 GAS 抗吞噬 M 蛋白的三个不同肽表位 - 分别来自 M1 和 M12 蛋白的氨基末端特异性序列,以及位于 M1 和 M12 蛋白高度保守的 C 末端重复区的 J14 肽(ASREAKKQVEKALE) - 与佐剂一起皮下递送至小鼠。此外,通过 ELISA 测定接种二价疫苗的小鼠的血清效价,然后完成对两种不同 GAS 血清型的调理作用和杀伤百分比。我们的数据表明,针对包含氨基酸和 M 蛋白保守 C 重复区的二价疫苗产生的抗血清能够杀死从广州人群中分离出的几种 GAS 菌株。因此,该二价疫苗可用于预防流行地区由 GAS 引起的疾病。我们成功构建了基于 M 蛋白的二价疫苗,该疫苗能够引起接种小鼠的高水平血清效价。因此,该疫苗有可能在我国用于预防 GAS 引起的疾病。

相似文献

1
Immunogenicity of a divalent group A streptococcal vaccine.A 型链球菌二价疫苗的免疫原性。
Rheumatol Int. 2013 Apr;33(4):1013-20. doi: 10.1007/s00296-012-2455-8. Epub 2012 Aug 8.
2
Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.M蛋白保守区抗体对泰国北部人群A组链球菌分离株的杀菌活性。
BMC Microbiol. 2006 Aug 9;6:71. doi: 10.1186/1471-2180-6-71.
3
Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.鼻内给药是一种有效的黏膜疫苗递送途径,用于针对A组链球菌M蛋白的自佐剂脂质核心肽。
J Infect Dis. 2006 Aug 1;194(3):316-24. doi: 10.1086/505580. Epub 2006 Jun 30.
4
Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes.多价A群链球菌疫苗可引发针对变异M亚型的杀菌抗体。
Clin Diagn Lab Immunol. 2005 Jul;12(7):833-6. doi: 10.1128/CDLI.12.7.833-836.2005.
5
A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.一种新型的经鼻内接种的A群9型链球菌活载体疫苗可保护小鼠免受9型A群链球菌的攻击感染。
Clin Vaccine Immunol. 2014 Sep;21(9):1343-9. doi: 10.1128/CVI.00330-14. Epub 2014 Jul 23.
6
Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.用四表位脂质核心肽疫苗构建体进行免疫接种可诱导针对A组链球菌的广泛保护性免疫反应。
J Infect Dis. 2006 Jun 15;193(12):1666-76. doi: 10.1086/504266. Epub 2006 May 10.
7
Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.通过鼻内免疫含有保守M蛋白B细胞表位且缺乏T细胞自身表位的肽疫苗来保护小鼠免受A组链球菌感染。
Vaccine. 2002 Jun 21;20(21-22):2816-25. doi: 10.1016/s0264-410x(02)00205-0.
8
M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.M蛋白保守区抗体可调理具有C重复序列变异的多株化脓性链球菌。
Res Microbiol. 2005 May;156(4):575-82. doi: 10.1016/j.resmic.2004.12.009. Epub 2005 Feb 19.
9
Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.用链球菌多表位重组蛋白进行免疫可保护小鼠免受A组链球菌侵袭性感染。
PLoS One. 2017 Mar 29;12(3):e0174464. doi: 10.1371/journal.pone.0174464. eCollection 2017.
10
Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.由包含10株表达源自A组链球菌的高度流行M蛋白抗原的乳酸乳球菌菌株的鼻内多价疫苗诱导的保护性免疫。
Microbiol Immunol. 2018 Jun;62(6):395-404. doi: 10.1111/1348-0421.12595. Epub 2018 Jun 11.

引用本文的文献

1
Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine.化学合成二价A群链球菌疫苗的免疫原性和安全性
Can J Infect Dis Med Microbiol. 2018 Feb 28;2018:4702152. doi: 10.1155/2018/4702152. eCollection 2018.

本文引用的文献

1
THE ANTIGENIC COMPLEX OF STREPTOCOCCUS HAEMOLYTICUS : I. DEMONSTRATION OF A TYPE-SPECIFIC SUBSTANCE IN EXTRACTS OF STREPTOCOCCUS HAEMOLYTICUS.溶血性链球菌的抗原复合体:I. 在溶血性链球菌提取物中证明一种具有型特异性的物质。
J Exp Med. 1928 Jan 1;47(1):91-103. doi: 10.1084/jem.47.1.91.
2
STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : I. ANTIGENIC RELATIONSHIPS BETWEEN STRAINS OF STREPTOCOCCUS HAEMOLYTICUS.链球菌生物学研究:I. 溶血链球菌菌株之间的抗原关系。
J Exp Med. 1919 Sep 1;30(3):179-213. doi: 10.1084/jem.30.3.179.
3
Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
朝着开发一种针对A组链球菌的抗疾病、阻断传播的鼻内疫苗的方向发展。
J Infect Dis. 2005 Oct 15;192(8):1450-5. doi: 10.1086/466528. Epub 2005 Sep 9.
4
Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop.A群链球菌疫苗的前景:理论依据、可行性及障碍——美国国立过敏与传染病研究所研讨会报告
Clin Infect Dis. 2005 Oct 15;41(8):1150-6. doi: 10.1086/444505. Epub 2005 Sep 2.
5
M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.M蛋白保守区抗体可调理具有C重复序列变异的多株化脓性链球菌。
Res Microbiol. 2005 May;156(4):575-82. doi: 10.1016/j.resmic.2004.12.009. Epub 2005 Feb 19.
6
Prospects for a group A streptococcal vaccine.A群链球菌疫苗的前景。
Curr Opin Mol Ther. 2005 Feb;7(1):11-6.
7
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.重组多价A群链球菌疫苗在健康成年人中的安全性和免疫原性:1期试验
JAMA. 2004 Aug 11;292(6):709-15. doi: 10.1001/jama.292.6.709.
8
Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.由活的重组乳酸乳球菌制成的黏膜疫苗可保护小鼠免受化脓性链球菌的咽部感染。
Infect Immun. 2004 Jun;72(6):3444-50. doi: 10.1128/IAI.72.6.3444-3450.2004.
9
Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.用多价A群链球菌疫苗进行鼻内免疫可保护小鼠免受鼻内激发感染。
Infect Immun. 2004 May;72(5):2507-12. doi: 10.1128/IAI.72.5.2507-2512.2004.
10
Current knowledge of type-specific M antigens of group A streptococci.A组链球菌特定类型M抗原的现有知识。
J Immunol. 1962 Sep;89:307-13.